Senti Bio Announces First Patient Dosed in Phase 1 Clinical Trial of SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia

May 13, 2024

https://www.globenewswire.com/news-release/2024/05/13/2880426/0/en/Senti-Bio-Announces-First-Patient-Dosed-in-Phase-1-Clinical-Trial-of-SENTI-202-for-the-Treatment-of-Relapsed-or-Refractory-Hematologic-Malignancies-Including-Acute-Myeloid-Leukemia.html

– SENTI-202 is a potential first-in-class Logic Gated off-the-shelf CAR-NK cell therapy –

– Initial clinical efficacy data expected by year-end 2024 and durability data expected in 2025 –

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.